Effect of intermittent cyclical disodium etidronate therapy on bone mineral density in men with vertebral fractures

Age and Ageing

Volumn 26, Issue 5, 1997, Pages 359-365

  Anderson, Frazer H ^a,d   Francis, Roger M ^a   Bishop, Janine C ^b   Rawlings, David J ^c  

^a FREEMAN HOSPITAL   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^d SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

Bone mineral density; Etidronate; Male; Osteoporosis; Vertebral fracture

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; CITRATE CALCIUM; CREATININE; ETIDRONIC ACID; HYDROXYPROLINE; PHOSPHATE;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BACKACHE; BONE DENSITY; BONE MINERAL; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CLINICAL ARTICLE; CREATININE URINE LEVEL; CRUSH TRAUMA; DRUG TOLERABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSPEPSIA; FEMUR NECK; FLATULENCE; FOLLOW UP; HUMAN; HYDROXYPROLINE URINE LEVEL; LUMBAR SPINE; MALE; METABOLIC BONE DISEASE; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; VERTEBRA FRACTURE;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; BONE DENSITY; CALCIUM CITRATE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ETIDRONIC ACID; FRACTURES, SPONTANEOUS; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; SPINAL FRACTURES; TREATMENT OUTCOME;

EID: 0030768767     PISSN: 00020729     EISSN: None     Source Type: Journal    
DOI: 10.1093/ageing/26.5.359     Document Type: Article

References (23)

1. Melton LJ, Chrischilles EA, Cooper C, Lane AW, Riggs BL. How many women have osteoporosis? J Bone Mineral Res 1992; 7: 1005-10.
2. Cooper C. Epidemiology and public health impact of osteoporosis. Bailliere's Clin Rheumatol Osteoporosis 1993; 7: 459-78.
3. Evans JG, Prudham D, Wandless I. A prospective study of fracture of the proximal femur: incidence and outcome. Public Health 1979; 93: 235-41.
4. Scane AC, Sutcliffe AM, Francis RM. The sequelae of vertebral crush fractures in men. Osteoporosis Int 1994; 4: 89-92.
5. Boyce WJ, Vessey MP. Rising incidence of fracture of the proximal femur. Lancet 1985; i: 150-1.
6. Obrant KJ, Bengner U, Johnell O, Nilsson BE, Sernbo I. Increasing age-adjusted risk of fragility fractures: a sign of increasing osteoporosis in successive generations? Calcif Tissue Int 1989; 44: 157-67.
7. Royal College of Physicians of London. Fractured neck of femur: prevention and management. London: Royal College of Physicians, 1989.
8. Seeman E. The dilemma of osteoporosis in men. Am J Med 1995; 98 (suppl. 2A): 76S-88S.
9. Fleisch H. Diphosphonates: history and mechanism of action. Metab Bone Dis Rel Res 1981; 4/5: 279-88.
10. Heaney RP, Saville PD. Etidronate disodium in postmenopausal osteoporosis. Clin Pharmacol Ther 1976; 20: 593-604.
11. Anderson C, Cape RDT, Crilly RG, Hodsman AB, Wolfe BM. Preliminary observations on a form of coherence therapy for osteoporosis. Calcif Tissue Int 1984; 36: 341-3.
12. Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990; 322: 1265-71.
13. Watts NB, Harris ST, Genant HK et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990; 323: 73-9.
14. Harris ST, Watts NB, Jackson RD, Genant HK, Wasnich RD, Ross P et al. Four year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med 1993; 95: 557-67.
15. Adachi JD, Cranney A, Goldsmith CH, Bensen WG, Bianchi F, Cividino A et al. Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss. J Rheumatol 1994; 21: 1922-6.
16. Eastell R, for UK Consensus Group on osteoporosis. Management of corticosteroid-induced osteoporosis. J Internal Med 1995; 237: 439-47.
17. Selby PL, Rehman MT, Economou G, Whitehouse RW, Adams JE, Adams PH et al. Etidronate in male osteoporosis: evidence for a site-specific action. In: Christiansen C, Riis B, eds. Proceedings of the Fourth International Symposium on Osteoporosis. Aalborg: Handelstrykkeriet, 1993; 105-8.
18. Baillie SP, Davison CE, Johnson FJ, Francis RM. Pathogenesis of vertebral crush fractures in men. Age Ageing 1992; 21: 139-41.
19. Matthews JNS. A refinement to the analysis of serial data using summary measures. Stat Med 1993; 12: 27-37.
20. Black DM, Cummings SR, Genant HK, Nevitt MC, Palermo L, Browner W. Axial and appendicular bone density predict fractures in older women. J Bone Mineral Res 1992; 7: 633-8.
21. Ross PD, Genant HK, Davis JW, Miller PD, Wasnich RD. Predicting vertebral fracture incidence from prevalent fractures and bone density among non-black, osteoporotic women. Osteoporosis Int 1993; 3: 120-6.
22. Anderson FH, Francis RM, Faulkner K. Androgen supplementation in eugonadal men with osteoporosis -effects of six months' treatment on bone mineral density and cardiovascular risk factors. Bone 1996; 18: 171-7.
23. Ringe JD, Kipshoven C, Rovati L, Setnikar I. Therapy of idiopathic male osteoporosis: a three-year study with calcium and low dose intermittent monofluorophosphate. Osteoporosis Int 6 (suppl. 1): 96.